Market Overview

Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure

Share:
Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure
Related QURE
64 Biggest Movers From Yesterday
Mid-Afternoon Market Update: Dow Up 240 Points; Uniqure Shares Spike Higher
Credit Suisse sees 18% upside in Abbott in premarket analyst action (Seeking Alpha)

Uniqure NV (NASDAQ: QURE) struck all-time highs last week and continued to linger near its peak value. One analyst projects 61-percent upside and considers the equity a top pick in 2018. 

The Rating

Chardan analyst Gbola Amusa maintained a Buy rating on uniQure and increased the price target from $37.50 to $50.

The Thesis

Amusa considers the year’s second half “ideal” for uniQure for 10 reasons.

  • Upcoming catalysts include second-half data from AMT-126 in a congestive heart failure study and submission of an investigational new drug application for AMT-130 in Huntington’s. Results on AMT-061 for hemophilia B are expected by the end of the year.
  • Post-proof-of-concept AAV-based gene therapy companies generally boast market caps between $1 billion and $8.4 billion, and uniQure’s $1.1-billion market cap is at the low end of the range.
  • Amusa predicted BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will bid to acquire or partner with uniQure this year.
  • Bristol-Myers Squibb Co (NYSE: BMY) could deepen its partnership, increase its stake in uniQure and provide long-term upside from progress in AMT-126.
  • Amusa expects uniQure, with a scaled manufacturing process, to beat Spark Therapeutics Inc (NASDAQ: ONCE) to market with its AAV-based hemophilia B gene therapy.
  • Hemophilia B presents a market opportunity north of $15 billion, and Amusa anticipates a path to reimbursement for AMT-061.
  • AMT-061 is seen to address patients with AAV5 antibodies, which would support best-in-class rankings.
  • AMT-061 has FDA breakthrough and EMA PRIME designations that expedite development.
  • The firm’s AAV-based Huntington’s product may prove superior to antisense oligonucleotides.
  • Management could monetize its intellectual property in manufacturing and generate royalties from peers.
  • The firm can stunt competitors with intellectual property in FIX-Padua.

Price Action

At the time of publication Monday, uniQure shares were trading down 0.13 percent at $31.03. 

Related Links:

The Size Effect Is Working With Health Care ETFs

Mergers, Acquisitions And A Tax Cut: Why This Biotech ETF Can Rebound

Latest Ratings for QURE

DateFirmActionFromTo
Nov 2018B. Riley FBRMaintainsBuyBuy
Sep 2018H.C. WainwrightMaintainsBuyBuy
Jul 2018Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for QURE
View the Latest Analyst Ratings

Posted-In: Chardan Gbola AmusaAnalyst Color Biotech Price Target Reiteration Analyst Ratings General Best of Benzinga

 

Related Articles (BMRN + BMY)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
DESPKeyBancInitiates Coverage On0.0
MELIKeyBancInitiates Coverage On0.0
ALBKeyBancMaintains120.0
AVNSKeyBancMaintains67.0
ABTCredit SuisseInitiates Coverage On82.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Should You Buy Germany ETFs On Optimistic GDP Outlook?

Bond Yield Rise Pauses, Dow Futures Get A Bit of Help From Some Earnings